Article
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
The New England journal of medicine - 15 May 2014
Afdhal Nezam, Zeuzem Stefan, Kwo Paul, Chojkier Mario, Gitlin Norman, Puoti Massimo, Romero-Gomez Manuel, Zarski Jean-Pierre, Agarwal Kosh, Buggisch Peter, Foster Graham R, Bräu Norbert, Buti Maria, Jacobson Ira M, Subramanian G Mani, Ding Xiao, Mo Hongmei, Yang Jenny C, Pang Phillip S, Symonds William T, McHutchison John G, Muir Andrew J, Mangia Alessandra, Marcellin Patrick
Abstract excerpt
BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection. METHODS: We conducted a phase 3, open-label study involving previously untreated patients with chronic HCV genotype 1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.